New genomic prostate cancer test improves risk assessment and surveillance
New prostate cancer test improves risk assessment — Tool tested by UC San Francisco helps identify those best suited for active surveillance – A new genomic test for prostate cancer can help predict whether men are more likely to harbor an aggressive form of the disease, according to a new UC San Francisco study. The test, which improves risk assessment when patients are first diagnosed, can also aid in determining which men are suitable for active surveillance – a way of managing the disease without direct treatment.